RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
999. Gordge MP, Neild GH: Platelet function in uraemia.
Platelets. 2:115-123, 1991.
1000. Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A:
Defective platelet adhesion on vessel subendothelium in
uremic patients. Blood. 68:337-42, 1986.
1001. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M,
Ponticelli C: Improvement in the haemostatic defect of uraemia
after treatment with recombinant human erythropoeitin.
Lancet 2:1227-1229, 1987.
1002. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J,
Revert L, y cols. Recombinant human erythropoietin treatment
improves platelet function in uremic patients. Kidney
International. 42:668-672, 1992.
1003. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G:
Moderate doses of aspirin and risk of bleeding in renal failure.
Lancet 1:414-416, 1986.
1004. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi
G: Aspirin prolongs bleeding time in uremia by a mechanism
distinct from platelet cyclooxygenase inhibition. J Clin.Invest
79:1788-1797, 1987.
1005. Sanchez Perales MC, Vazquez E, Garcia Cortes MJ, Borrego
FJ, Borrego J, Perez DB y cols. Platelet antiaggregation and
hemorrhagic risk in hemodialysis. Nefrologia. 22:456-462,
2002.
1006. Vane JR: Inhibition of prostaglandin synthesis as a mechanism
of action of aspirin-like drugs. Nature New Biol
23:232-235, 1971.(Abstract)
1007. Moncada S, Vane JR: Pharmacology and endogenous roles of
prostaglandin endoperoxides, thromboxane A2, and prostacyclin.
Pharmacol.Rev. 30:293-331, 1979.
1008. Antiplatelet Trialists'Collaboration: Collaborative overview of
randomised trials of antiplatelet therapy I:Prevention of
death, myocardial infarction, and stroke by prolonged antiplatelet
therapy in various categories of patients. BMJ
308:81-106, 1994.
1009. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens
CH: The Effect of Chronic Platelet Inhibition with Low-Dose
Aspirin on Atherosclerotic Progression and Acute
Thrombosis - Clinical Evidence from the Physicians' Health
Study. Am Heart J 122:1588-1592, 1991.
1010. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW,
Signorello LB, y cols. Acetaminophen, aspirin, and chronic
renal failure. N Engl J Med. 345:1801-1808, 2001.
1011. ISIS-2 Collaborative Group: Randomised trial of intravenous
streptokinase, oral aspirin, oth, or neither amongst 17,187
cases of suspected acute myocadial infarction: ISIS-2.
Lancet 2:349-360, 1988.
1012. Harker LA: Therapeutic inhibition of platelet function in stroke.
Cerebrovascular.Diseases. 8:8-18, 1998.
1013. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An
update on aspirin in the primary prevention of cardiovascular
disease. Arch.Intern.Med. 163:2006-2010, 2003.
1014. Antiplatelet Trialists'Collaboration: Collaborative overview of
randomised trials of antiplatelet therapy II:Maintenance of
vascular graft or arterial patency by antiplatelet therapy. BMJ
308:159-168, 1994.
1015. Escolar G, Heras M: Clopidogrel: A selective inhibitor of platelet
ADP receptors. Drugs of today 36:187-199, 2000.
1016. Herbert JM: Clopidogrel and antiplatelet therapy. Expert
Opin Invest Drug 3:449-455, 1994.
1017. Schror K: Clinical pharmacology of the adenosine diphosphate
(ADP) receptor antagonist, clopidogrel. Vasc.Med.
3:247-251, 1998.
1018. CAPRIE Steering Committee.: A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischaemic
events (CAPRIE). Lancet 348:1329-1339, 1996.
1019. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y,
y cols. Clopidogrel, a novel antiplatelet and antithrombotic
agent. Cardiovasc.Drug.Rev. 2:180-198, 1993.
1020. Hankey GJ, Sudlow CL, Dunbabin DW: Thienopyridines or
aspirin to prevent stroke and other serious vascular events in
patients at high risk of vascular disease? A systematic review
of the evidence from randomized trials. Stroke 31:1779-
1784, 2000.
1021. CURE Steering Committee. Effects of clopidogrel in addition
to aspirin in patients with acute coronary syndromes without
ST-segment elevation. N Engl J Med. 345, 494-502. 2001.
1022. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH,
Investigators FT: Double-blind study of the safety of clopidogrel
with and without a loading dose in combination with
aspirin compared with ticlopidine in combination with aspirin
after coronary stenting : the clopidogrel aspirin stent
international cooperative study (CLASSICS). Circulation
102:624-629, 2000.
1023. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A,
Wilmer C, y cols. (CREDO Trial): Early and sustained dual
oral antiplatelet therapy following percutaneous coronary
intervention: a randomized controlled trial. JAMA
288:2411-2420, 2002.
1024. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers.
Lancet 353:227-231, 1999.
1025. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W,
Holt R, y cols. Pharmacodynamic Study of F(Ab')2 Fragments
of Murine Monoclonal Antibody-7E3 Directed Against
Human Platelet Glycoprotein- Iib/Iiia in Patients with
Unstable Angina Pectoris. J.Clin.Invest. 86:651-659, 1990.
1026. Brener SJ, Ellis SG, Schneider J, Apperson-Hansen C, Topol
EJ: Abciximab-facilitated percutaneous coronary intervention
and long-term survival--a prospective single-center
registry. Eur.Heart J 24:630-638, 2003.
1027. Best PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, y
cols. Safety of abciximab in patients with chronic renal
insufficiency who are undergoing percutaneous coronary
interventions. Am.Heart J 146:345-350, 2003.
1028. The EPIC Investigators: Use of a monoclonal antibody directed
against the platelet glycoprotein IIb-IIIa receptor in high-risk
coronary angioplasty. N Engl J Med. 330:956-961, 1994.
1029. The CAPTURE Investigators: Randomised placebo-controlled
trial of abciximab before and during coronary intervention in
refractory unstable angina: the CAPTURE Study. Lancet
349:1429-1435, 1997.
1030. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa recetor
blockade and low-dose heparin during percutaneous
coronary revascularization. N Engl J Med. 336:1689-1696,
1997.
1031. The EPISTENT Investigators: Randomised controlled trial to
assess safety of coronary stenting with use of abciximab.
Lancet 352:85-90, 1998.
1032. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips
DR, Nannizi L, y cols. Design of potent and specific integrin
antagonists. Peptide antagonists with high specificity for
glycoprotein IIb-IIIa. J.Biol.Chem. 268:1066-1073, 1993.
218